Cargando…

Genetic risk for atrial fibrillation could motivate patient adherence to warfarin therapy: a cost effectiveness analysis

BACKGROUND: Atrial fibrillation (AF) increases risk of stroke, and although this stroke risk can be ameliorated by warfarin therapy, some patients decline to adhere to warfarin therapy. A prospective clinical study could be conducted to determine whether knowledge of genetic risk for AF could increa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiffman, Dov, Perez, Marco V., Bare, Lance A., Louie, Judy Z., Arellano, Andre R., Devlin, James J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587718/ https://www.ncbi.nlm.nih.gov/pubmed/26419225 http://dx.doi.org/10.1186/s12872-015-0100-7

Ejemplares similares

Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis
por: Shiffman, Dov, et al.
Publicado: (2016)

Concordance of Cardiovascular Risk Factors and Behaviors in a Multiethnic US Nationwide Cohort of Married Couples and Domestic Partners
por: Shiffman, Dov, et al.
Publicado: (2020)

Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
por: Lee, Siew Ling, et al.
Publicado: (2021)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
por: Pundi, Krishna N., et al.
Publicado: (2021)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Warfarin and atrial fibrillation: from ideal to real the warfarin affaire
por: Molteni, Mauro, et al.
Publicado: (2014)

Gaps in Dyslipidemia Care Among Working‐Aged Individuals With Employer‐Sponsored Health Care
por: Shiffman, Dov, et al.
Publicado: (2020)

The use of warfarin in veterans with atrial fibrillation
por: Bravata, Dawn M, et al.
Publicado: (2004)

The cost of monitoring warfarin in patients with chronic atrial fibrillation in primary care in Sweden
por: Björholt, Ingela, et al.
Publicado: (2007)

Analysis of 17,576 Potentially Functional SNPs in Three Case–Control Studies of Myocardial Infarction
por: Shiffman, Dov, et al.
Publicado: (2008)

An Insulin Resistance Score Improved Diabetes Risk Assessment in the Malmö Prevention Project—A Longitudinal Population-Based Study of Older Europeans
por: Shiffman, Dov, et al.
Publicado: (2021)

Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in China
por: Zhao, Shujuan, et al.
Publicado: (2017)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
por: Hallinen, Taru, et al.
Publicado: (2016)

The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective
por: Casciano, Julian P., et al.
Publicado: (2013)

Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin
por: Reddy, Vivek Y., et al.
Publicado: (2016)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
por: Kleintjens, Joris, et al.
Publicado: (2013)

Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
por: Wei, Hongtao, et al.
Publicado: (2021)

All-Cause and Bleeding-Related Health Care Costs in Warfarin-Treated Patients with Atrial Fibrillation
por: Ghate, Sameer R., et al.
Publicado: (2011)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
por: Fitzgerald, P., et al.
Publicado: (2020)

Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history
por: Tada, Hayato, et al.
Publicado: (2016)

Warfarin Adherence Among Patients with Atrial Fibrillation in Rural Area of Dongyang, China: A Questionnaire-Based Study
por: Chen, Huadong, et al.
Publicado: (2022)

Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis
por: Mendoza-Sanchez, Jose, et al.
Publicado: (2018)

The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
por: Jaberi, Neda, et al.
Publicado: (2021)

Initiation and Persistence with Warfarin Therapy in Atrial Fibrillation According to Ethnicity
por: Hansen, Carolina Malta, et al.
Publicado: (2012)

Improving outpatient warfarin use for hospitalized patients with atrial fibrillation
por: Touchette, Daniel R., et al.
Publicado: (2008)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation
por: Patel, Priya, et al.
Publicado: (2017)

Characteristics of warfarin under-prescription in older adults with atrial fibrillation
por: Rashid, Sana, et al.
Publicado: (2021)

THU300 Assessment Of NAFLD Burden In An Employee Wellness Program Among Non-obese Patients Without Evident Metabolic Abnormalities
por: Bril, Fernando, et al.
Publicado: (2023)

Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
por: Laliberté, François, et al.
Publicado: (2015)

The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study
por: Shiffman, Dov, et al.
Publicado: (2011)

A Gene Variant in CERS2 Is Associated with Rate of Increase in Albuminuria in Patients with Diabetes from ONTARGET and TRANSCEND
por: Shiffman, Dov, et al.
Publicado: (2014)

Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
por: You, Joyce H. S., et al.
Publicado: (2012)

Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
por: Weir, Matthew R., et al.
Publicado: (2021)

Cost-effectiveness of Direct Oral Anticoagulant vs. Warfarin Among Atrial Fibrillation Patients With Intermediate Stroke Risk
por: Choi, Ju Hee, et al.
Publicado: (2022)

Validation of a genetic risk score for atrial fibrillation: A prospective multicenter cohort study
por: Muse, Evan D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_aa72h2ni7uffh1lvsf5e8l7d7o